Rhumbline Advisers Purchases 1,938 Shares of Enovis Co. (NYSE:ENOV)

Rhumbline Advisers boosted its holdings in shares of Enovis Co. (NYSE:ENOV) by 1.3% during the 4th quarter, Holdings Channel reports. The fund owned 152,628 shares of the company’s stock after buying an additional 1,938 shares during the period. Rhumbline Advisers’ holdings in Enovis were worth $6,697,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ENOV. UMB Bank n.a. raised its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after buying an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Enovis during the 3rd quarter worth $55,000. FMR LLC boosted its position in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Enovis in the third quarter valued at about $217,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Down 4.9 %

NYSE:ENOV opened at $40.03 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $63.96. The company has a market cap of $2.28 billion, a PE ratio of -18.28 and a beta of 1.94. The company’s 50 day moving average is $44.90 and its two-hundred day moving average is $44.34.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.